OncoMatch/Clinical Trials/NCT04288726
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Is NCT04288726 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD30.CAR-EBVST cells for extranodal natural killer/t-cell lymphoma, nasal type.
Treatment: CD30.CAR-EBVST cells — This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Required: CD30 positive
CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory
Prior therapy
Cannot have received: investigational cell therapy or vaccine
Received an investigational cell therapy or vaccine within the past 6 weeks
Cannot have received: investigational small molecule drug
Received an investigational small molecule drug within the past 2 weeks
Cannot have received: CD30 antibody-based therapy
Received CD30 antibody-based therapy within the previous 4 weeks
Cannot have received: gemcitabine-containing chemotherapy
Received gemcitabine-containing chemotherapy within the previous 12 weeks
Lab requirements
Kidney function
Estimated GFR > 70 mL/min.
Liver function
Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal. AST 3 times or less than the upper limit of normal.
Cardiac function
EKG shows no significant arrhythmias
Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal. AST 3 times or less than the upper limit of normal. Estimated GFR > 70 mL/min. EKG shows no significant arrhythmias
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Hospital · Houston, Texas
- Texas Children's Hospital · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify